Use Cases
Immune
Immune Resilience and Inflammation
Frequent infections and chronic inflammatory conditions drive interest here — and this category has more real clinical use behind it than most.
CEarly Human ResearchReviewed September 1, 2026
Compounds used for this goal
The reason
Why people use it
- Thymosin alpha-1 is the standout: it is a licensed medicine in a number of countries and has been used clinically as an immune modulator in hepatitis and sepsis contexts.
- VIP draws interest for airway and inflammatory conditions, having reached clinical trials in pulmonary arterial hypertension and sarcoidosis.
- KPV is discussed for gut and skin inflammation on the strength of animal models of colitis and dermatitis.
The evidence
What the research shows
- Thymosin alpha-1 has the broadest human record of any compound in this group, including randomised trials and meta-analyses in sepsis and chronic hepatitis B with mixed but real results.
- VIP's clinical trial record is small, and results have not established an approved indication in most jurisdictions.
- KPV human evidence is essentially absent; the case rests on animal and cell models.
- Immune modulation cuts both ways — stimulating an immune system is not automatically desirable, particularly in autoimmune disease.
Reported use
How it is reported to be used
- Thymosin alpha-1 is reported as subcutaneous injection in short courses, mirroring how it is used clinically where licensed.
- VIP is most often reported intranasally in the context of chronic sinus and airway complaints.
- Reported use is typically seasonal or episodic rather than continuous.
Our reading
Evidence verdict
CEarly Human ResearchSmall, early-phase or single-centre human studies only. Findings are preliminary.
Early human research overall, with thymosin alpha-1 substantially better supported and actually licensed in some countries.
Before you read further
Cautions and open questions
- In autoimmune conditions, immune stimulation is a plausible route to worsening disease, and no data reassure on this point.
- Recurrent infections warrant real immunological evaluation before any compound.
- Licensure in one country does not make research-use-only material an approved medicine anywhere else.
Sources
Referenced research
- Randomised controlled trial
Thymosin alpha-1 in sepsis: randomised evidence
- Clinical trial
Vasoactive intestinal peptide clinical trials
Educational content only. This page is not medical advice, a protocol or an individualised dosing recommendation. Reported use patterns summarise published literature and community reporting; they are not verified clinical cases and are not endorsements. Speak to a qualified healthcare professional about your own health.
All use cases